ABSTRACT
The specific activity of new drug forms (tablets, suppositories, ointments) of dubinal was studies on models of ischemic damage to the heart, toxic hepatitis, aseptic inflammation, damage to the skin and mucosa of the large intestine. It was found that the drug forms under study possessed a cardioprotective, hepatoprotective, anti-inflammatory, and wound-healing effect. This may serve as a prerequisite to their further clinical study.
Subject(s)
Antioxidants/administration & dosage , Butylated Hydroxytoluene/administration & dosage , Animals , Asepsis , Carbon Tetrachloride Poisoning/complications , Carbon Tetrachloride Poisoning/drug therapy , Chemical and Drug Induced Liver Injury/drug therapy , Chemical and Drug Induced Liver Injury/etiology , Disease Models, Animal , Drug Evaluation, Preclinical , Inflammation/chemically induced , Inflammation/drug therapy , Intestinal Diseases/drug therapy , Mice , Myocardial Infarction/drug therapy , Myocardial Infarction/etiology , Myocarditis/chemically induced , Myocarditis/drug therapy , Ointments , Rats , Suppositories , Tablets , Time Factors , Ulcer/drug therapyABSTRACT
A procedure for quantitative assay of gentamicin sulfate was developed. It is based on formation of an ionic associate with bromothymol blue followed by chloroform extraction and the photometric determination at 420-422 nm. The relative error does not exceed 0.94 and 0.98 per cent in regard to the substance and its dosage form (gynecological suppositories), respectively. Optimal conditions for the assay were elaborated i.e. the ratio of the reagent and extraction agent, the time and the number of the extractions and pH of the medium. The process obeys to the main law of light absorption within the concentration of gentamicin sulfate in aqueous solution equal to 8-128 micrograms/ml.
